MedPath

A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs

Not Applicable
Completed
Conditions
HIV Infections
Registration Number
NCT00002411
Lead Sponsor
Bristol-Myers Squibb
Brief Summary

The purpose of this study is to compare the safety of didanosine plus stavudine plus nelfinavir (NLF) with that of zidovudine plus lamivudine plus NLF. This study also examines how long these drug combinations are effective in lowering viral load (level of HIV in the blood).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (32)

Sorra Research Ctr / Med Forum

🇺🇸

Birmingham, Alabama, United States

Body Positive

🇺🇸

Phoenix, Arizona, United States

Hill Top Research Inc

🇺🇸

Fresno, California, United States

UCLA Med Ctr / CARE BH-412 CHS

🇺🇸

Los Angeles, California, United States

AIDS Healthcare Foundation

🇺🇸

Los Angeles, California, United States

West Los Angeles VAMC

🇺🇸

Los Angeles, California, United States

Sherman Oaks Hosp Research Institute

🇺🇸

Sherman Oaks, California, United States

Harbor UCLA Med Ctr / Research and Educational Institute

🇺🇸

Torrance, California, United States

Yale New Haven Hosp / Nathan Smith Clinic

🇺🇸

New Haven, Connecticut, United States

GW Med Ctr / Clinical Trials Unit

🇺🇸

Washington, District of Columbia, United States

Scroll for more (22 remaining)
Sorra Research Ctr / Med Forum
🇺🇸Birmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.